Serial BNP measurements during doxorubicin chemotherapy detected early cardiac damage in lymphoma patients before clinical symptoms appeared, potentially enabling early intervention.
Early detectionBNP rose before echocardiographic changes or symptoms appeared, providing a window for intervention during doxorubicin chemotherapy
What the researchers found
Serial BNP measurements detected doxorubicin-induced cardiotoxicity before clinical symptoms or echocardiographic changes in 30 lymphoma patients, with BNP rising progressively with cumulative drug exposure.
Why it matters
Doxorubicin is one of the most effective cancer drugs but causes irreversible heart damage. A simple blood test that detects early cardiac injury could allow dose adjustments before permanent damage occurs, saving both hearts and lives.
How the study worked
Prospective cohort study in 30 non-Hodgkin's lymphoma patients receiving CHOP chemotherapy. Serial ANP, BNP, and echocardiography performed throughout treatment up to cumulative doxorubicin doses of 400-500 mg/m².
What this study cannot tell us
30 patients — moderate sample. ANP was less useful. Specific BNP cutoff values for clinical decision-making were not established. Not all types of cardiotoxicity may be detected by BNP.
How to read the evidence
Moderate evidence from a prospective cohort study with serial measurements in a clinically relevant population, limited by moderate sample size.
When this study was published
Published in 1999. Cardiac biomarker monitoring during chemotherapy has become increasingly standard, with troponin and BNP/NT-proBNP both used clinically.
The bigger picture
Cardio-oncology — protecting the heart during cancer treatment — is a growing medical field. BNP monitoring during chemotherapy represents a practical, inexpensive approach to preventing treatment-related heart failure.
Questions still open
- Should BNP monitoring be standard during anthracycline chemotherapy?
- What BNP cutoff should trigger dose reduction?
- Can early intervention based on BNP prevent irreversible cardiotoxicity?
Common questions
Can chemotherapy damage the heart?
How does BNP testing help?
Read the original research
Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin's lymphoma.
European journal of haematology, 62(2), 135-41
Citation
Nousiainen, T; Jantunen, E; Vanninen, E; Remes, J; Vuolteenaho, O; Hartikainen, J. (1999). Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin's lymphoma.. European journal of haematology, 62(2), 135-41.